Alzheimer’s disease market across 8MM to hit 19.3b by 2033

DMTs are expected to account for 73.5% of the global market.

The global Alzheimer's disease (AD) market across the eight major markets (8MM) is projected to reach $19.3b by 2033 at a compound annual growth rate of 23.4%, according to GlobalData.

The expansion is attributed to the introduction of expensive disease-modifying therapies (DMTs), an ageing population, and the launch of new symptomatic therapies for agitation and psychosis associated with AD.

DMTs are expected to account for 73.5% of the global market, with a significant portion of this share being dominated by drugs targeting amyloid beta. However, unmet needs beyond treatment access remain.

The new DMTs are viewed as moderately effective, sparking ongoing demand for more potent therapies that not only slow progression but aim to halt the disease entirely.

Moreover, there is a continued need for drugs that improve cognition in the disease’s later stages and offer more effective treatments for secondary symptoms such as agitation and psychosis.

8MM = US, France, Germany, Italy, Spain, UK, Japan, and China